인도의 원료의약품(API) 시장 : 점유율 분석, 산업 동향 및 통계 데이터, 성장 예측(2026-2031년)

The India API market size is expected to grow from USD 14.18 billion in 2025 to USD 15.28 billion in 2026 and is forecast to reach USD 22.18 billion by 2031 at 7.74% CAGR over 2026-2031.

Solid policy incentives, accelerating export demand and rapid capacity additions collectively underpin this growth trajectory. The Production Linked Incentive (PLI) scheme is releasing patient capital for green-field plants and bulk-drug parks, compressing logistics costs and improving utility access for producers. At the same time, U.S. and European buyers are moving sourcing away from China after passage of the Biosecure Act, resulting in a 50% jump in request-for-quotation volumes at leading Indian contract manufacturers during 2024. Domestic firms are also upgrading fermentation, containment and continuous-manufacturing assets to capture premium Oncology and Biotech volumes, while AI-enabled process control is shaving cycle time and energy consumption. Counter-pressures stem from volatile prices of China-sourced key starting materials (KSMs) and compliance gaps at MSME facilities, yet both forces are driving the sector toward vertical integration and quality-system upgrades that strengthen long-run competitiveness.

India Active Pharmaceutical Ingredients (API) Market Trends and Insights

Government PLI & Bulk-Drug-Park Push for Self-Reliance

Thirty-two PLI projects worth Rs 4,024 crore are operational, exceeding originally sanctioned investment and enabling domestic synthesis of critical molecules such as Penicillin G for the first time in three decades. Bulk-drug parks in Gujarat, Himachal Pradesh and Andhra Pradesh provide solvent-recovery units, effluent treatment and common utilities that lower operating costs. Aurobindo Pharma's new 15,000 tpa Pen-G block exemplifies the turnaround in self-reliance. Import dependence on critical intermediates is forecast to halve once the green-field assets reach nameplate utilization, and the Ministry of Commerce & Industry pegs cumulative private pharma investment at Rs 1.61 lakh-crore since 2021. Faster environmental clearances and single-window approvals shorten project gestation, reinforcing policy impact.

Accelerated Shift of U.S./EU Orders to India Post-Biosecure Act

The 2024 U.S. Biosecure Act restricts federal procurement from firms tied to Chinese biotech entities, compelling originators to diversify supply chains. Indian producers, already running more than 750 U.S. FDA-approved sites, have seen a 50% spike in RFQs and audits since Q3 2024. Cost-per-kg parity favors India; landed quotes sit roughly 20% below Chinese averages for similar quality grades. Regulatory tech-transfer cycles still take 18-24 months, yet India's dossier experience compresses timelines relative to first-time entrants. As Western sponsors sequence departures from Chinese suppliers, rolling contracts give Indian CDMOs multi-year revenue visibility.

Volatile Cost of China-Sourced KSMs Despite Localization

Even with rising domestic capacity, India imported APIs worth Rs 377 billion in FY 2024, roughly 35% of total demand. A sudden 15-20% price surge in fermentation inputs during early 2025 compressed operating margins that analysts expected to climb to 12-14%. Larger corporates hedge via multi-region contracts and captive intermediate blocks; MSMEs, lacking scale, shutter production or defer capacity upgrades, disrupting supply chains. Delays in full PLI park commissioning mean dependence will persist through 2026, keeping input costs volatile.

Other drivers and restraints analyzed in the detailed report include:

1. Scale-up in Oncology HPAPI Blocks (Visakhapatnam & Hyderabad)
2. Growth of CRDMO Exports Serving Phase I/II Innovators
3. Persistent Compliance Gaps at MSME API Units (WHO-GMP)

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Merchant suppliers currently contribute under 39% of output but will post a 9.42% CAGR as originators divest legacy synthesis blocks in favor of variable-cost models. The India API market benefits when CDMOs assume regulatory dossier maintenance, validation batches and periodic site audits, freeing sponsor capital for biologics and digital therapeutics launches. Increasingly, innovators bundle early-stage chemistry, toxicology and Phase-I supply under single-vendor contracts that reward scale CDMOs with end-to-end capabilities. Captive manufacture remains viable for high-volume statins or metformin where single-plant economies outweigh transaction overhead. Nevertheless, stricter environmental mandates and inflationary utility tariffs tilt total cost of ownership toward merchant operators. Piramal Pharma Solutions' USD 80 million sterile-injectables expansion in Kentucky underscores the scalability of outsourced platforms to serve global demand.

Second-order benefits include flexible tech-transfer windows, which help sponsors stagger launch waves across geographies, thereby smoothing utilization at merchant sites. The India API market also sees deeper backward integration among top CDMOs; reactor parks now co-locate with solvent-recovery and effluent incineration to streamline EH&S audits. Conversely, captive plants grapple with latent contamination risks tied to product-mix complexity, compelling larger quality-control staffing and higher cost per batch.

Synthetic chemistry still anchors 72.80% of 2025 revenue due to lower capital intensity and well-trodden regulatory precedent. Yet biotech APIs, logging a 9.18% CAGR, will capture incremental value as monoclonal antibodies, recombinant hormones and mRNA vectors reach late-stage trials. Continuous-manufacturing skids and high-throughput crystallizers compress synthetic batch cycles, while fermentation reactors adopt real-time metabolite sensors to boost titers. Laurus Bio's extra 120-crore fermentation block aims at amino-acid and enzyme intermediates demanded by biologics pipelines.

Regulatory complexity remains higher for biotech APIs, necessitating validated viral-clearance steps and advanced characterization platforms. However, price premiums of 3-5 X versus synthetic actives offset added capex. The India API market diversifies risk as hybrid manufacturers leverage existing small-molecule lines to cushion biotech scale-up volatility. Meanwhile, synthetic producers pursue green catalysts and micro-reactor technology to maintain cost leadership.

The India API Market Report is Segmented by Business Model (Captive API, Merchant/Contract API), Synthesis Type (Synthetic APIs, Biotech APIs), Drug Type (Generic, Branded, Biosimilar), Therapeutic Area (Oncology, Anti-Infectives, Cardio-Metabolic, CNS, Respiratory, Others), End-Use (Formulation Companies Domestic, Export-Oriented Formulators, CRDMOs/CDMOs), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Divi's Laboratories Ltd
2. Aurobindo Pharma
3. Laurus Labs Ltd
4. Dr Reddy's Laboratories Ltd
5. Sun Pharmaceuticals Industries
6. Viatris India (Agila)
7. Teva API India
8. Lupin
9. Cipla
10. Zydus Group
11. Intas Pharmaceuticals
12. Piramal Group
13. Biocon Biologics
14. Samsung Biologics India JV
15. Syngene International
16. Torrent Pharmaceuticals
17. Granules India
18. Glenmark Active Pharma Ingredients
19. Hetero Drugs
20. Alembic Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Government PLI & Bulk-Drug-Park push for self-reliance
  • 4.2.2 Accelerated shift of US/EU orders to India post-Biosecure Act
  • 4.2.3 Scale-up in oncology HPAPI blocks (Visakhapatnam, Hyderabad clusters)
  • 4.2.4 Growth of CRDMO exports serving Phase-I/II innovators
  • 4.2.5 Green-chemistry route adoption to lower solvent import bill
  • 4.2.6 AI-driven process-optimization cutting cycle-times <=20 %
• 4.3 Market Restraints
  • 4.3.1 Volatile cost of China-sourced KSMs despite localization
  • 4.3.2 Persistent compliance gaps at MSME API units (WHO-GMP)
  • 4.3.3 Talent crunch in large-molecule downstream & containment
  • 4.3.4 Rising energy tariffs eroding margins in West-coast plants
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory & Technological Outlook
• 4.6 Porter's Five Forces
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Business Model
  • 5.1.1 Captive API
  • 5.1.2 Merchant / Contract API
• 5.2 By Synthesis Type
  • 5.2.1 Synthetic API
  • 5.2.2 Biotech API
• 5.3 By Molecule Size
  • 5.3.1 Small-Molecule
  • 5.3.2 Large-Molecule / Biologic
• 5.4 By Potency
  • 5.4.1 High-Potency API
  • 5.4.2 Low/Medium Potency API
• 5.5 By Therapeutic Area
  • 5.5.1 Oncology
  • 5.5.2 Cardiovascular
  • 5.5.3 Infectious Diseases
  • 5.5.4 Metabolic Disorders
  • 5.5.5 CNS & Neurology
  • 5.5.6 Respiratory
  • 5.5.7 Others
• 5.6 By End-User
  • 5.6.1 Pharma & Biopharma Companies
  • 5.6.2 CDMOs / CMOs
  • 5.6.3 CROs & Academia
  • 5.6.4 Export-Oriented Formulators
  • 5.6.5 CRDMOs / CDMOs

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level overview, Market level overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Divi's Laboratories Ltd
  • 6.3.2 Aurobindo Pharma Ltd
  • 6.3.3 Laurus Labs Ltd
  • 6.3.4 Dr Reddy's Laboratories Ltd
  • 6.3.5 Sun Pharmaceutical Industries Ltd
  • 6.3.6 Viatris India (Agila)
  • 6.3.7 Teva API India
  • 6.3.8 Lupin Ltd
  • 6.3.9 Cipla Ltd
  • 6.3.10 Cadila Pharmaceuticals
  • 6.3.11 Intas Pharmaceuticals
  • 6.3.12 Piramal Pharma Solutions
  • 6.3.13 Biocon Biologics
  • 6.3.14 Samsung Biologics India JV
  • 6.3.15 Syngene International
  • 6.3.16 Torrent Pharma
  • 6.3.17 Granules India
  • 6.3.18 Glenmark Active Pharma Ingredients
  • 6.3.19 Hetero Drugs
  • 6.3.20 Alembic Pharma

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment